What do systematic reviews say?

Intervention not reported

• Extracorporeal photopheresis versus standard treatment for acute graft‐versus‐host disease after haematopoietic stem… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Intervention not reported

• Extracorporeal photopheresis versus alternative treatment for chronic graft‐versus‐host disease after haematopoietic… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Mycophenolate mofetil vs methotrexate

Mycophenolate mofetil showed no clear difference in overall survival compared with methotrexate (low certainty).

• Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving allogeneic… 2014 · Cochrane Headline outcomes only
  HR 0.73 [0.45, 1.17]
  2 studies · 129 participants
  Low

Intervention not reported

The intervention showed no clear difference in overall survival (at 36 months) (moderate certainty).

• Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or… 2023 · Cochrane Headline outcomes only
  HR 0.93 [0.77, 1.13]
  9 studies · 1249 participants
  Moderate

Dinutuximab‐containing immunotherapy vs usual care

Dinutuximab‐containing immunotherapy probably leads to lower overall survival (reported as mortality) compared with standard therapy (moderate certainty).

• Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated… 2019 · Cochrane Headline outcomes only
  HR 0.5 [0.31, 0.8]
  1 study · 226 participants
  Moderate

Low molecular weight heparin vs placebo or no treatment

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Glutamine vs placebo

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Fresh frozen plasma vs no treatment

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Antithrombin III plus heparin vs heparin

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Heparin vs low molecular weight heparin

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Heparin vs prostaglandin E1

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Low molecular weight heparin vs prostaglandin E1

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Ursodeoxycholic acid vs placebo or no treatment

Summary of findings: Ursodeoxycholic acid showed no clear difference in overall survival ( compared with placebo or no treatment (low certainty).

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  HR 0.83 [0.59, 1.18]
  3 studies · 474 participants
  Low

Summary of findings: Defibrotide vs no treatment

Summary of findings: Defibrotide showed no clear difference in overall survival ( compared with no treatment (low certainty).

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  HR 1.04 [0.54, 2.02]
  1 study · 356 participants
  Low

High‐dose chemotherapy vs chemotherapy without bone marrow transplant or stem cell rescue

High‐dose chemotherapy showed no clear difference in overall survival at 5‐year compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).

• High‐dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for… 2016 · Cochrane Headline outcomes only
  RR 1 [0.96, 1.04]
  8 studies · 3566 participants
  High

Intervention not reported

The intervention showed no clear difference in overall survival (high certainty).

• Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma soft… 2017 · Cochrane Headline outcomes only
  HR 1.26 [0.7, 2.29]
  1 study · 83 participants
  High

Intervention not reported

The intervention showed no clear difference in overall survival (moderate certainty).

• High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for follicular… 2012 · Cochrane Headline outcomes only
  HR 0.97 [0.76, 1.22]
  3 studies · 701 participants
  Moderate

Heparin vs no treatment

It is very uncertain whether summary of findings: Heparin changes overall survival ( compared with no treatment (very low certainty).

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  HR 0.65
  1 study · 161 participants
  Very low

Retinoic acid post‐consolidation therapy vs no further treatment

Retinoic acid postconsolidation therapy showed no clear difference in overall survival (reported as mortality) compared with no further treatment (low certainty).

• Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic… 2017 · Cochrane Headline outcomes only
  HR 0.87 [0.46, 1.63]
  1 study · 98 participants
  Low